

HEREDITARY ANGIOEDEMA AGENTS PRIOR AUTHORIZATION FORM (form effective 7/15/2024)

Prior authorization guidelines for Hereditary Angioedema (HAE) Agents and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at <u>https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.html</u>.

New request Renewal request	# of pages:	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength:	Dosage fo	orm:	
Dose/directions:		Quantity:		Refills:
Diagnoses (<u>submit documentation</u>):		Dx codes (<u>required</u>):		
What is the beneficiary's weight?				kg / Ibs
Has the beneficiary been taking the requested medication within the past 90 days?		Yes Submit documentation and date No of last dose.		
Is the requested medication prescribed by or in consultation with an allergist/immunologist, dermatologist, or hematologist?		YesSubmit documentation ofNoconsultation, if applicable.		
Will the beneficiary be using the requested medication with any other HAE Agents for the same indication (ie, more than 1 HAE Agent for <u>acute treatment</u> OR more than 1 HAE Agent for <u>long-</u>		☐Yes – please list:		
term prophylaxis)?		□No		

Complete all sections that apply to the beneficiary and this request.

Check all that apply and submit documentation for each item.

INITIAL requests

Requested medication is being used for short-term prophylaxis (e.g., surgical or dental procedure)

Has a diagnosis of **HAE Type I or Type II** (with C1 inhibitor deficiency/dysfunction) AND:



FAX FORM AND CLINICAL DOCUMENTATION

Has a low C1 esterase inhibitor antigenic level (mg/dL) obtained on 2	separate occasions
Has a low C1 esterase inhibitor functional level (<65% [unless alread	/ using an androgen or CT esterase inhibitor]) obtained on 2
Has a diagnosis of HAE Type III (with normal C1 inhibitor) AND:	
Has a normal C4 complement level (mg/dL)	
Has a normal C1 esterase inhibitor antigenic level (mg/dL)	
Has a normal C1 esterase inhibitor functional level	
Has a history of recurrent angioedema without urticaria	
One of the following:	
Both of the following:	
Has a family history of HAE	
Failed to respond to maximum recommended doses of antihistant	nines (eg, cetirizine 20 mg twice daily)
Has an HAE-causing genetic mutation	
One of the following:	
Is not taking an estrogen-containing medication (hormone replacement, ca	ontraceptives, etc.)
<u>Is</u> taking an estrogen-containing medication (hormone replacement, contra	aceptives, etc.) that is medically necessary for the
beneficiary's indication – specify indication:	
Is not taking an ACE inhibitor (benazepril, enalapril, lisinopril, quinapril, ramipri	, etc.)
Is using the requested medication for long-term prophylaxis AND:	
Has poorly controlled HAE despite use of an HAE Agent for on demand/ad	cute treatment
For a non-preferred HAE Agent:	
Has a history of trial and failure of or contraindication or intolerance to the	preferred agents in this class that are approved or medically
accepted for treatment of the beneficiary's condition (Refer to https://papo	I.com/preferred-drug-list for a list of preferred and non-
preferred agents in this class.)	
RENEWAL request	
Is using the requested medication for long-term prophylaxis AND:	
Experienced fewer HAE attacks since starting the requested medication	
Is using the requested medication for acute treatment AND:	
Experienced a positive clinical response to the requested medication	
PLEASE <u>FAX</u> COMPLETED FORM WITH <u>REQUIRED CLIN</u>	CAL DOCUMENTATION TO 866-240-3712
Prescriber Signature:	Date:

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.